by
Brendon Nafziger, DOTmed News Associate Editor | July 08, 2010
Weekly shipments of moly
coming soon.
Lantheus Medical Imaging, Inc inked a deal with radiopharmaceutical producer MDS Nordion to provide weekly shipments of molybdenum-99 only a day after the Canadian government announced it had
approved the National Research Universal Reactor to go back online.
Today, N. Billerica, Mass.-based Lantheus said it had signed an agreement with MDS Nordion to ship Mo-99 once the NRU reactor, in Chalk River, Ontario, is up and running again, likely by the end of July.
"We look forward to working with MDS Nordion to increase access to Mo-99 supply once the NRU reactor returns to service," Bill Dawes, vice president of manufacturing and supply chain for Lantheus, said in a statement.
The agreement will last until next July.
Ottawa-based MDS Nordion, which also supplies material for equipment sterilization, said it had already begun arranging logistics for shipments in advance of the reactor's restart.
Mo-99 is the parent isotope of technetium-99m, used in 80 percent of all diagnostic radiopharmaceutical injections, Lantheus said.
Mo-99 is processed in Lantheus' TechneLite and Cardiolite technetium-99m generators, which are distributed to hospitals and radiopharmacies.
